References
- Glidewell O, Holland J F. Comparative prognosis of the acute leukemias. Bibl Haematol 1975; 527–-530
- Estey E H, Keating M J, McCredie K B, Bodey G P, Freireich E J. Causes of initial remission induction failure in acute myelogenous leukemia. Blood 1982; 60: 309–315
- Lichtman M A, Heal J, Rowe J M. Hyperleukocytic leukaemia: rheological and clinical features and management. Baillieres Clin Haematol 1987; 1: 725–746
- Ventura G J, Hester J P, Smith T L, Keating M J. Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction. Am J Hematol 1988; 27: 34–37
- McLeod B C, Strauss R G, Ciavarella D, Gilcher R O, Kasprisin D O, Kiprov D D, et al. Management of hematological disorders and cancer. J Clin Apheresis 1993; 8: 211–230
- Cuttner J, Holland J F, Norton L, Ambinder E, Button G, Meyer R J. Therapeutic leukapheresis for hyperleukocytosis in acute myelocytic leukemia. Med Pediatr Oncol 1983; 11: 76–78
- Eisenstaedt R S, Berkman E M. Rapid cytoreduction in acute leukemia. Management of cerebral leukostasis by cell pheresis. Transfusion 1978; 18: 113–115
- Meyer R J, Cuttner J, Truog P, Ambinder E P, Holland J F. Therapeutic leukopheresis of acute myelo-monocytic leukemia in pregnancy. Med Pediatr Oncol 1978; 4: 77–83
- Hug V, Keating M, McCredie K, Hester J, Bodey G P, Freireich E J. Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte count. Cancer 1983; 52: 773–779
- Estey E, Trujillo J M, Cork A, O'Brien S, Beran M, Kantarjian H, et al. AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes. Hematol Pathol 1992; 6: 43–48
- Estey E H, Keating M J, Dixon D O, Trujillo J M, McCredie K B, Freireich E J. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia. Hematol Pathol 1987; 1: 203–208
- Keating M J, Smith T L, Kantarjian H, Cork A, Walters R, Trujillo J M, et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 1988; 2: 403–412
- Estey E, de Lima M, Strom S, Pierce S, Freireich E J, Keating M J. Long-term follow-up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas M.D. Anderson Cancer Center. Cancer 1997; 80: 2176–2180
- Estey E H, Thall P F, Reed P, Kantarjian H, Beran M, Pierce S, et al. Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy. Leukemia 1999; 13: 850–854
- Estey E H, Thall P F, Pierce S, Cortes J, Beran M, Kantarjian H, et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999; 93: 2478–2484
- Estey E H, Shen Y, Thall P F. Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB [In Process Citation]. Blood 2000; 95: 72–77
- Estey E, Smith T L, Keating M J, McCredie K B, Gehan E A, Freireich E J. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia 1989; 3: 257–263
- Wilhelm M, Kantarjian H M, O'Brien S, Pierce S, Keating M J, Freireich E J, et al. Pneumonia during remission induction chemotherapy in patients with AML or MDS. Leukemia 1996; 10: 1870–1873
- Anderlini P, Ghaddar H M, Smith T L, Pierce S, Kantarjian H M, O'Brien S, et al. Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first. Leukemia 1996; 10: 964–969
- Grambsch P M. Goodness-of-fit and diagnostics for proportional hazards regression models. Cancer Treat Res 1995; 75: 95–112
- Hern B. Therapeutic leukapheresis in the patient with leukemia. J Intraven Nurs 1996; 19: 269–272
- Nagase K, Sawada K, Ohnishi K, Egashira A, Ohkusu K, Shimoyama T. Complications of leukocytapheresis. Ther Apher 1998; 2: 120–124
- Porcu P, Danielson C F, Orazi A, Heerema N A, Gabig T G, McCarthy L I. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol 1997; 98: 433–436